Lightnews — Scholar-powered news

pharmaphorum @pharmaphorum.bsky.social · 7h

Fresh from a return to #oncology with the FDA approval of #Hernexeos as a treatment for HER2-positive non-small cell #lungcancer (NSCLC), #BoehringerIngelheim is racing to expand its label, with #Bayer in hot pursuit.

pharmaphorum.com/news/esmo-bo...

ESMO: Boehringer, Bayer seek first-line HER2+ NSCLC role

New trial data backs the use of Boehringer Ingelheim's new oral HER2 inhibitor Hernexeos in front-line treatment of HER2+ NSCLC, but Bayer is in hot pursuit.

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 7h

Results from the #PATHFINDER2trial of #Grail's #bloodtest for multiple cancers have shown greater efficacy and a lower rate of false alarms than in an earlier trial of the technology.

pharmaphorum.com/news/esmo-gr...

ESMO: Grail's data on cancer blood test firms up

Data from a new phase 3 trial of Grail's blood test for multiple cancers show improved efficacy and a lower rate of false alarms than a prior study.

pharmaphorum.com

2

pharmaphorum @pharmaphorum.bsky.social · 8h

#EliLilly's CDK4/6 inhibitor #Verzenio reduced the risk of death by 15.8% when used as adjuvant treatment for early-stage HR-positive, HER2-negative #breastcancer, according the reveal of data from the #monarchEtrial.

pharmaphorum.com/news/esmo-li...

pharmaphorum @pharmaphorum.bsky.social · 1d

ViiV's injectable HIV PrEP Apretude will soon be an alternative for people in England and Wales who cannot use daily oral options.

pharmaphorum.com/news/viivs-b...

ViiV's bimonthly HIV PrEP jab cleared for use by NHS

ViiV's injectable HIV PrEP Apretude will soon be an alternative for people in England and Wales who cannot use daily oral options.

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 1d

Researchers have evidence that a sample of menstrual blood could allow a diagnosis of #endometriosis within weeks, rather than years, and guide new drug development.
pharmaphorum.com/news/could-e...

Could endometriosis be diagnosed with a simple test?

pharmaphorum.com

1

pharmaphorum @pharmaphorum.bsky.social · 1d

AI-powered autonomous lab firm Lila Sciences upsizes its Series A to $350m, heading a bumper week for new biotech financings.

pharmaphorum.com/news/lila-sc...

pharmaphorum @pharmaphorum.bsky.social · 1d

Merck KGaA has become the third drugmaker to reach a deal with the Trump administration to cut medicine costs, offering discounts on fertility drugs.

pharmaphorum.com/news/merck-j...

Merck joins the Trump MFN gang with IVF deal

Merck KGaA has become the third drugmaker to reach a deal with the Trump administration to cut medicine costs, offering discounts on fertility drugs.

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 1d

The #FDA has named the first products to take advantage of its recently announced Commissioner's national priority voucher programme.

pharmaphorum.com/news/fda-han...

pharmaphorum @pharmaphorum.bsky.social · 2d

Thousands of people in the #UK have joined a #lawsuit against #JohnsonandJohnson, alleging that it knowingly sold #talc products, contaminated with asbestos, that caused #cancer.

pharmaphorum.com/news/jj-face...

J&J faces fresh litigation in UK over talc cancer risks

Thousands of people in the UK have joined a lawsuit against Johnson & Johnson, claiming that it knowingly sold talc products that caused cancer.

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 2d

A private equity investment consortium has raised a takeover offer for Denmark's #BavarianNordic, but some shareholders are still reluctant to sell.

pharmaphorum.com/news/bavaria...

Bavarian Nordic urges investors to accept takeover offer

A private equity investment consortium has raised a takeover offer for Denmark's Bavarian Nordic, but some shareholders are still reluctant to sell

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 2d

#NovoNordisk has boosted its pipeline by paying $340m upfront for rights to an #Omeros drug for PNH and other rare blood and kidney disorders.

pharmaphorum.com/news/novo-bu...

Novo builds pipeline again with $2.1bn Omeros deal

Novo Nordisk has boosted its pipeline by paying $340m upfront for rights to an Omeros drug for PNH and other rare blood and kidney disorders

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 3d

A #UK government-backed #initiative to train a new generation of #skilledworkers in #medicinesmanufacturing has been taken up by around 1,200 people since it started 18 months ago.

pharmaphorum.com/news/uks-vr-...

UK's VR-powered medicine maker scheme delivers first results

A UK initiative to train a new generation of workers in medicines manufacturing has been taken up by around 1,200 people since it started last year.

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 3d

#EliLilly has built the case for its oral #GLP1 agonist #orforglipron with two more phase 3 readouts, including new data showing that it can improve blood glucose compared to a go-to therapy for #type2diabetes.

Lilly says oral GLP-1 could be 'foundational' diabetes drug

Eli Lilly has built the case for its oral GLP-1 orforglipron with two more phase 3 readouts, including a head-to-head win over Farxiga in diabetes.

buff.ly

pharmaphorum @pharmaphorum.bsky.social · 3d

Munich-based antibody-drug conjugate (#ADC) specialist #Tubulis has raised an impressive €308 million ($358 million) to help fund clinical trials of its cancer therapies, led by #ovariancancer candidate TUB-040.

pharmaphorum.com/news/germany...

Germany's Tubulis raises €308m for ADC pipeline

Ahead of a data reveal at ESMO, Tubulis has raised €308m to help fund clinical trials of its antibody-drug conjugate for ovarian cancer.

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 3d

Johnson & Johnson has said it wants to spin off its orthopaedics division as part of an effort to redirect its business towards higher-growth areas.

pharmaphorum.com/news/jj-stre...

J&J streamlines with plan to hive off orthopaedics unit

Johnson & Johnson has said it wants to spin off its orthopaedics division as part of an effort to redirect its business towards higher-growth areas.

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 3d

A phase 3 study suggests #Pfizer's underperforming HER2 inhibitor Tukysa could play a role in first-line maintenance of HER2-positive breast cancer.

pharmaphorum.com/news/can-new...

Can new Tukysa data drop unlock its sales potential?

A phase 3 study suggests Pfizer's underperforming HER2 inhibitor Tukysa could play a role in first-line maintenance of HER2-positive breast cancer

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 4d

#KaileraTherapeutics has raised an eye-watering $600 million in Series B #financing to take its lead drug for #weightloss into pivotal trials, in a further sign of the insatiable investor appetite for #obesity-related stocks.

$600m round will help Kailera push obesity drug into phase 3

Kailera Therapeutics has raised an eye-watering $600 million in Series B financing to take its lead drug for weight loss into pivotal trials.

buff.ly

pharmaphorum @pharmaphorum.bsky.social · 4d

Activist investor #ShahCapital has called on the #board of directors at #Novavax to put the company up for sale, citing a "litany of missteps" at the company.

pharmaphorum.com/news/investo...

Investor seeks sale of Novavax after poor COVID jab sales

Investor Shah Capital has called on Novavax's board to put the company up for sale, citing a "litany of missteps" at the vaccine developer.

pharmaphorum.com

2

pharmaphorum @pharmaphorum.bsky.social · 4d

That's a wrap for today's webinar. Thank you all for following along. If you want to revisit the session, the entire webinar will be available to view on demand here: www.brighttalk.com/webcast/9977... #ppwebinar

Tracking studies get smarter: AI meets human intelligence

What the future looks like as AI and technology continue to elevate insights for faster, smarter decisions.

www.brighttalk.com

pharmaphorum @pharmaphorum.bsky.social · 4d

How can you validate the responses of synthetic patients, asks once audience member? Kelly Warth answers that this is something that is being addressed, with pilots emerging. But these are in the early stages of development. #ppwebinar

pharmaphorum @pharmaphorum.bsky.social · 4d

Tamara Burke notes that it's a good sign to hear research teams asking questions around creativity and pushing the boundaries to create more engaging research. We have to work together, she adds #ppwebinar

pharmaphorum @pharmaphorum.bsky.social · 4d

What platforms or resources would the panel recommend to improve survey design? Mo Rice, admitting her own bias, spotlights an in-house co-pilot. But adds that you must be very careful to ensure that it is a closed and paid for model to ensure confidentiality #ppwebinar

pharmaphorum @pharmaphorum.bsky.social · 4d

Each platform can do something better than another, so it really depends on the clients needs, agrees Mo Rice, but a key focus should be whether a platform is robust enough for the healthcare space #ppwebinar

pharmaphorum @pharmaphorum.bsky.social · 4d

What are gold standard examples of AI technologies? While the panel is hesitant to name drop specific companies, Warth says that it depends on the definition of gold standard is for each user #ppwebinar

pharmaphorum @pharmaphorum.bsky.social · 4d

AI has to be curated in the right way to be successful. It has to be fed the right information, with human intervention to make sure it is giving us the right outcomes says Warth #ppwebinar